Skip to main content
TipRanks
Go Ultimate75% OFF

PDS Biotechnology (EU6) Q1 2026 Earnings Report

2 Followers

DE:EU6 Q1 2026 EPS Results

Actual EPS
-EUR 0.12
Consensus EPS
-EUR 0.13
Beat/Miss
Beat by +EUR 0.01
One Year Ago EPS
-EUR 0.19

DE:EU6 Q1 2026 Revenue Results

Actual Revenue
EUR 0
Expected Revenue
EUR 0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q1 2026
Date
05/13/2026
Time
Before Open
Conference Call
Wednesday, May 13, 2026
DE:EU6 Upcoming Earnings

PDS Biotechnology's next earnings date is estimated for April 1, 2027, based on past reporting schedules.

Q1 2026 Earnings Call Audio

DE:EU6 Q1 2026 Earnings Call
0:00 / 0:00

Q1 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q1 2026 Earnings Call Summary

Q1 2026
Earnings Call Date:May 13, 2026|% Change Since:-38.58%|
Earnings Call Sentiment|Positive

The call conveyed meaningful clinical and intellectual property progress: a strategic protocol amendment for VERSATILE-003 that reduces patient count (~28.6%) and time to an interim readout, peer-reviewed and encouraging clinical data for PDS01ADC, strengthened IP extending PDS0101 protection into the 2040s, and established manufacturing processes. Financially, operating expenses and net loss improved year-over-year. Key risks include a relatively modest cash balance ($21.7M), continued unprofitability with rising interest expense, the need for OS data for full approval and additional confirmatory trials, and competition in the HPV16 head and neck space. On balance, the operational and clinical positives outweigh the near-term financial and development risks.

Company Guidance

Management guided that the VERSATILE‑003 amendment adopts progression‑free survival as an interim co‑primary endpoint (retaining overall survival for full approval) to enable a potential accelerated approval, changes randomization from 2:1 to 1:1 and reduces planned enrollment from ~350 to ~250 patients to shorten duration, lower external and internal costs and speed an interim readout (sites remained engaged and enrollment is restarting); they reiterated PDS0101’s differentiators (only late‑stage HPV16 HNSCC regimen that is subcutaneous and requires just five doses) and noted new U.S. and Japanese patents extending PDS0101 market protection into the 2040s. Financial metrics include cash of $21.7M as of March 31, 2026, a Q1 net loss of ~$7.3M ($0.13 per share) versus $8.5M ($0.21) year‑ago, R&D of $3.5M (vs $5.8M), G&A of $3.1M (vs $3.3M), total operating expenses of $6.5M (vs $9.1M) and net interest expense of $0.8M (vs $0.6M); operational guidance also highlighted an established Versamune manufacturing process with CMC validation/scale‑up ahead of a BLA and that PDS01ADC data (JCO Oncology Advances, NCI/AACR) support advancement—colorectal Stage 2 is fully enrolled with additional data expected by year‑end.

  • Protocol amendment for VERSATILE-003 to enable faster path to approvalAmended trial to add progression-free survival (PFS) as an interim co-primary endpoint while retaining overall survival (OS) for full approval; randomization changed from 2:1 to 1:1 and planned enrollment reduced from ~350 to ~250 patients (≈28.6% reduction), expected to shorten duration and lower trial costs and time to an interim readout.
  • Clinical momentum and site retentionSites remained with the program through a pause and are preparing to restart enrollment following the FDA-aligned amendment, supporting continued recruitment momentum for VERSATILE-003.
  • PDS0101 program: unique product attributes and IP protectionPDS0101 is the only late-stage investigational HPV16-positive HNSCC therapy requiring five doses and administered subcutaneously; new U.S. and Japanese patents granted and anticipated biologics exclusivity extend market protection into the 2040s.
  • PDS01ADC: positive clinical data and peer-reviewed publicationPromising results reported for PDS01ADC in colorectal cancer (Stage 1 data published in JCO Oncology Advances) and encouraging early results in metastatic castration-resistant prostate cancer (NCI-led study); colorectal Stage 2 cohort fully enrolled with additional data expected by year-end.
  • Manufacturing and CMC readiness for VersamuneCommercial manufacturing process is established and scale-up has been performed; remaining work focuses on validation and CMC activities in parallel with Phase III to support a BLA filing, described as a straightforward path to commercialization.
  • Improved operating expense profile and smaller net lossNet loss improved to $7.3M ($0.13 per share) in Q1 2026 from $8.5M ($0.21) in Q1 2025 (net loss decrease ≈14.1%; loss per share improved ≈38.1%); total operating expenses declined to $6.5M from $9.1M (≈28.6% reduction).
  • Lower R&D and G&A spendR&D expense decreased to $3.5M from $5.8M (≈39.7% reduction) primarily due to lower clinical and manufacturing costs; G&A decreased modestly to $3.1M from $3.3M (≈6.1% reduction).

DE:EU6 Earnings History

DE:EU6 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Apr 01, 20272026 (Q4)-0.05--0.12――
Nov 13, 20262026 (Q3)-0.08-0.10-0.1742.11% (+0.07)
Aug 13, 20262026 (Q2)-0.12-0.16-0.1914.29% (+0.03)
May 13, 20262026 (Q1)-0.13-0.12-0.1938.10% (+0.07)
Mar 30, 20262025 (Q4)-0.18-0.12-0.1938.10% (+0.07)
Nov 13, 20252025 (Q3)-0.18-0.17-0.2634.48% (+0.09)
Aug 13, 20252025 (Q2)-0.21-0.19-0.218.70% (+0.02)
May 14, 20252025 (Q1)-0.22-0.19-0.2730.00% (+0.08)
Mar 27, 20252024 (Q4)-0.25-0.19-0.3240.00% (+0.13)
Nov 14, 20242024 (Q3)-0.27-0.26-0.3217.14% (+0.05)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed